Verrica Pharmaceuticals Settles Litigation, Dormer Labs Halts US Sales of Cantharidin Products
Portfolio Pulse from Benzinga Newsdesk
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) has settled litigation with Dormer Laboratories, Inc., resulting in Dormer halting the sale of cantharidin-containing products in the US.
July 01, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verrica Pharmaceuticals has settled litigation with Dormer Labs, leading to Dormer halting the sale of cantharidin-containing products in the US. This could reduce competition for Verrica's products.
The settlement reduces competition for Verrica's cantharidin-containing products in the US market, which could positively impact VRCA's market share and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100